Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pharma Proff
www.pharmaproff.com/
Pharma Proff
enquiry@pharmaproff.com
+1-888-778-7886

Bookmark and Share
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage.

BriefingWire.com, 7/26/2019 - p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis.

Download the sample report @ [URL]https://www.pharmaproff.com/request-sample/1195[/URL]

Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various adverse events.

The major challenge is prevention of tissue damage by selectively modulating p53 activity, under pathophysiological conditions that generate redox stress.

Get the detailed analysis @ [URL]https://www.pharmaproff.com/report/p53-antigen-modulators[/URL]

p53 antigen modulator therapies are being widely studied for the development of various target specific cancer therapies. Dendritic cell-derived vaccines, adenoviral p53 vectors, MDM2 inhibitors and small-molecules to reinstate the DNA binding activity of p53 are some commercial approaches as p53 antigen modulator therapies, for the treatment of various indications. Also, research studies have demonstrated that novel therapeutic strategies are being developed to overcome the challenges related to in-depth knowledge of p53 and associated pathways.

Make enquiry before purchase @ [URL]https://www.pharmaproff.com/enquiry/1195[/URL]

Quark Pharmaceuticals Inc. is developing QPI-1002 as a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the pro-apoptotic gene p53, for the treatment of delayed graft function and acute kidney injury. Some of the companies having a therapeutic pipeline of p53 antigen modulators include Innovation Pharmaceuticals Inc., Aprea Therapeutics, and Actavalon Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

About Us:

Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2024 Proserve Technology, Inc.